Recently, Regorafenib which is an oral multikinase inhibitor that blocks the activity of protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumour immunity is also accepted for patients with unresectable HCC [3, 17]. The gene discussed is WEE1; the disease is hepatocellular carcinoma.